These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 11868336)

  • 1. HIV-1 infection and low steady state viral loads.
    Callaway DS; Perelson AS
    Bull Math Biol; 2002 Jan; 64(1):29-64. PubMed ID: 11868336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opportunistic infection as a cause of transient viremia in chronically infected HIV patients under treatment with HAART.
    Jones LE; Perelson AS
    Bull Math Biol; 2005 Nov; 67(6):1227-51. PubMed ID: 16023709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mathematical analysis of antiretroviral therapy aimed at HIV-1 eradication or maintenance of low viral loads.
    Wein LM; D'Amato RM; Perelson AS
    J Theor Biol; 1998 May; 192(1):81-98. PubMed ID: 9628841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling the long-term control of viremia in HIV-1 infected patients treated with antiretroviral therapy.
    Di Mascio M; Ribeiro RM; Markowitz M; Ho DD; Perelson AS
    Math Biosci; 2004; 188():47-62. PubMed ID: 14766093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.
    Laurichesse JJ; Persoz A; Theodorou I; Rouzioux C; Delfraissy JF; Meyer L
    HIV Med; 2007 May; 8(4):213-9. PubMed ID: 17461848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Naive T-cell depletion related to infection by X4 human immunodeficiency virus type 1 in poor immunological responders to highly active antiretroviral therapy.
    Delobel P; Nugeyre MT; Cazabat M; Sandres-Sauné K; Pasquier C; Cuzin L; Marchou B; Massip P; Cheynier R; Barré-Sinoussi F; Izopet J; Israël N
    J Virol; 2006 Oct; 80(20):10229-36. PubMed ID: 17005700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART.
    Chew CB; Potter SJ; Wang B; Wang YM; Shaw CO; Dwyer DE; Saksena NK
    J Clin Virol; 2005 Jul; 33(3):206-16. PubMed ID: 15911442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A viral load-based cellular automata approach to modeling HIV dynamics and drug treatment.
    Shi V; Tridane A; Kuang Y
    J Theor Biol; 2008 Jul; 253(1):24-35. PubMed ID: 18083195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 compartmentalization in diverse leukocyte populations during antiretroviral therapy.
    Potter SJ; Lemey P; Achaz G; Chew CB; Vandamme AM; Dwyer DE; Saksena NK
    J Leukoc Biol; 2004 Sep; 76(3):562-70. PubMed ID: 15218056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel approach to HIV therapy: highly active antiretroviral therapy and autologous hematopoietic cell transplantation.
    Pippi F
    Med Hypotheses; 2008; 70(2):291-3. PubMed ID: 17681707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up.
    Resino S; Resino R; Micheloud D; Gurbindo Gutiérrez D; Léon JA; Ramos JT; Ciria L; de José I; Mellado J; Muñoz-Fernández A;
    Clin Infect Dis; 2006 Mar; 42(6):862-9. PubMed ID: 16477566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Côte d'Ivoire.
    Adjé-Touré CA; Cheingsong R; Garcìa-Lerma JG; Eholié S; Borget MY; Bouchez JM; Otten RA; Maurice C; Sassan-Morokro M; Ekpini RE; Nolan M; Chorba T; Heneine W; Nkengasong JN
    AIDS; 2003 Jul; 17 Suppl 3():S49-54. PubMed ID: 14565609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms involved in the low-level regeneration of CD4+ cells in HIV-1-infected patients receiving highly active antiretroviral therapy who have prolonged undetectable plasma viral loads.
    Benveniste O; Flahault A; Rollot F; Elbim C; Estaquier J; Pédron B; Duval X; Dereuddre-Bosquet N; Clayette P; Sterkers G; Simon A; Ameisen JC; Leport C
    J Infect Dis; 2005 May; 191(10):1670-9. PubMed ID: 15838794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highly active antiretroviral therapy started during pregnancy or postpartum suppresses HIV-1 RNA, but not DNA, in breast milk.
    Shapiro RL; Ndung'u T; Lockman S; Smeaton LM; Thior I; Wester C; Stevens L; Sebetso G; Gaseitsiwe S; Peter T; Essex M
    J Infect Dis; 2005 Sep; 192(5):713-9. PubMed ID: 16088820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The distribution of viral blips observed in HIV-1 infected patients treated with combination antiretroviral therapy.
    Percus JK; Percus OE; Markowitz M; Ho DD; Di Mascio M; Perelson AS
    Bull Math Biol; 2003 Mar; 65(2):263-77. PubMed ID: 12675332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West Africa.
    Seyler C; Adjé-Touré C; Messou E; Dakoury-Dogbo N; Rouet F; Gabillard D; Nolan M; Toure S; Anglaret X
    AIDS; 2007 May; 21(9):1157-64. PubMed ID: 17502726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cd38 expression on Cd8+ T cells in Human immunodeficiency virus 1-positive adults treated with HAART.
    Beran O; Holub M; Spála J; Kalanin J; Stanková M
    Acta Virol; 2003; 47(2):121-4. PubMed ID: 14524479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.